JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3009 Sorafenib
2 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥23.25 mg/mL
B4904 ACTB-1003

Target: VEGFR|FGFR|Tie-2|RSK|p70 S6K

Summary: FGFR1 inhibitor

insoluble in H2O; ≥18.15 mg/mL
B5832 Altiratinib
1 Citation

Target: FLT3|VEGFR|Trk Receptors|c-MET|Tie-2

Summary: c-MET/TIE-2/VEGFR inhibitor

≥21.55 mg/mL
B5835 AZD2932

Target: FLT3|VEGFR|PDGFR|c-Kit

Summary: inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit

Soluble in DMSO
C3342 MAZ51

Target: VEGFR

Summary: VEGFR3 antagonist

insoluble in EtOH; insoluble in H2O; ≥31.4 mg/mL
A3632 Motesanib

Target: VEGFR

Summary: Inhibitor of Flk-1/Flt-4/PDGFR-/c-Kit

≥42 mg/mL
A3843 SU 5402

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR2/FGFR/PDGFR/EGFR inhibitor

insoluble in EtOH; insoluble in H2O; ≥14.8 mg/mL
A3847 SU5416

Target: VEGFR

Summary: VEGF receptor inhibitor and AHR agonist

insoluble in EtOH; insoluble in H2O; ≥11.9 mg/mL
A3954 ZM323881

Target: VEGFR

Summary: VEGFR-2/KDR inhibitor,potent and selective

Soluble in DMSO
A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL